We conducted a prospective study to assess the prognostic impact of selected copy number variations (CNVs) in Stage II-III microsatellite stable (MSS) colon cancer. A total of 401 patients were included from 01/2004 to 01/2009. The CNVs in 8 selected target genes, DCC/18q, EGFR/7p, TP53/17p, BLK/8p, MYC/8q, APC/5q, ERBB2/17q and STK6/20q, were detected using a quantitative multiplex polymerase chain reaction of short fluorescent fragment (QMPSF) method. The primary end-point was the impact of the CNVs on the 4-year disease-free survival (DFS). The recurrence rate at 4 years was 20.9%, corresponding to 14% Stage II patients versus 31% Stage III patients (p < 0.0001). The 4-year DFS was significantly decreased in patients with a loss at DCC/18q (p 5 0.012) and a gain at ERBB2/17q (p 5 0.041). The multivariate analysis demonstrated that Stage III, a loss at DCC/18q and a gain at ERBB2/17q were independent factors associated with DFS. A combination of DCC/18q and ERBB2/17q was also associated with relapse, with the hazard ratio increasing from 1 to 2.4 (95% confidence interval (CI), 1.5-4.1) and 3.1 (95% CI, 1.2-8.4) in the presence of 0, 1 or 2 alterations, respectively (p 5 0.0013). CNVs in DCC/18q and ERBB2/17q are significantly associated with DFS in Stage II-III MSS colon cancer.
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Colon cancer is one of the most common malignancies worldwide, with approximately 1.4 million cases diagnosed each year. 1 Surgical resection followed by adjuvant chemotherapy is the standard of care for Stage III and high-risk Stage II diseases, with a 5-year disease-free survival (DFS) rate of 73.3%. 2, 3 Until now, the TNM classification has been the only validated tool for making decisions about chemotherapy in an adjuvant setting, and no molecular markers are systematically recommended for sporadic cases. Indeed, it is useful to know the microsatellite status when chemotherapy with 5-fluorouracil alone is proposed. Alternatively, although KRAS and BRAF mutations have been recently reported as negative prognostic factors, their detection is not yet being systematically performed in the absence of a specific treatment or follow-up in these subgroups. 4, 5 Colon cancer is a molecularly heterogeneous disease with different molecular subtypes and involves sequential genetic and epigenetic events that are still not yet fully understood. 6, 7 Using whole genome expression analyses, at least six molecular subtypes have been recently reported. Although new pathways were identified, they still overlap with already known classifications, such as chromosomal instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype (CIMP) pathways. [8] [9] [10] Among these forms of genetic instability, CIN is present in approximately 80% of colon cancers, with <3% of cancers displaying both CIN and MSI. 11, 12 One common form of structural variation due to CIN is the copy number variation (CNV), which is defined by a loss or gain of DNA regions occurring in focal or large chromosomal regions. Previous studies showed that several recurrent CNVs are commonly observed in primary carcinomas or liver metastases. In microsatellite stable (MSS) tumors, the recurrent CNVs that have been observed in >25% of samples were mainly gains at 7p, 7q, 8p, 17q and 20q and losses at 8p, 17p and 18q. 13, 14 In a study on Stage II/III colorectal cancers, Watanabe et al. reported that a single analysis of a loss in a chromosomal region was less informative than a global detection of the CIN severity for predicting DFS. 15 Considering that the KRAS and BRAF status were not determined, they found that a high level of CIN, based on the ratio of the losses detected at 2p, 5q, 18q and 17p, was a marker of recurrence and survival. 15 In a study of 1,188 Stage II/III colorectal cancer patients, Mouradov et al. reported that the MSI phenotype and a high level of CIN at 5q, 17p or 18q were independent markers for DFS, whereas mutations in KRAS, NRAS, BRAF, PIK3CA and TP53 were not. 16 Although these results support the hypothesis that CIN may have prognostic value in Stage II/III colorectal cancers, no definitive conclusions can be made because they used a retrospective design, a mix of colon and rectal tumors and different markers. Indeed, while surgery is recommended as the primary treatment for localized colon cancer, preoperative chemoradiotherapy is often performed for rectal tumors. In addition to these clinical differences, it has also been shown that rectal and colon cancers differ in their molecular patterns, particularly for the BRAF mutation, MSI and CIMP phenotypes. 17 Accordingly, it is now established that studies on subtypes are more relevant in determining new markers and/or strategies than those on mixed cohorts. In this context, we previously developed a quantitative multiplex polymerase chain reaction method that enables the simultaneous detection of CNVs in selected genes in patients with colon cancers. 18 The main CNVs in 2p, 5q, 17p and 18q that were reported by previous studies were integrated in the method. 15, 16 Moreover, CNVs at 7p, 8q, 17q and 20q were also used because they are frequently altered and have potential clinical interest. 13, 14, 18 The aim of this prospective study was to evaluate the impact of CIN in MSS Stage II/III colon cancer by analyzing a combination of selected CNVs in several genes, including gains at 7p, 8q, 17q and 20q and losses at 5q, 8p, 17p and 18q. The mutational status of KRAS and BRAF was integrated into the analysis.
Material and Methods

Patients
The study was conducted from January 2004 to January 2009 in three centers. The inclusion criteria were patients with histologically proven Stage II (T3-T4, N0, M0) and III (T any, N1 or N2, M0) colon carcinomas with an MSS phenotype. All of the patients had undergone a complete surgical resection of the primary tumor, and the primary tumor had formalin-fixed, paraffin-embedded sections, as well as frozen tumors and matched normal tissue. Follow-up was performed according to national guidelines, with visits every 3 months for 2 years, followed by every 6 months for 5 years. Patients with a history of hereditary cancers and/or a cancer in the 3 years preceding their inclusion were excluded. All of the common baseline clinical data and the outcomes at each visit of the follow-up were collected. All of the included patients provided written informed consent. The study was approved by the Northwest I Institutional Review Board in France.
Analysis of CNVs in genes
The CNV analysis was centralized and based on the detection of gains and losses in genes located at 7p, 8q, 17q and 20q and at 5q, 8p, 17p and 18q, respectively. The CNVs were detected using the somatic quantitative multiplex polymerase chain reaction of short fluorescent fragments (QMPSF) method, as previously described. [18] [19] [20] Briefly, the QMPSF method is based on the simultaneous quantitative amplification of short target genomic sequences using dye-labeled primers. PCR was performed with DNA extracted from frozen tumor samples and normal tissue. For each patient, electropherograms were used to identify a loss or gain in the amplicons for each of the following selected target genes in the tumors and were compared with the amplicons from the normal tissue after adjusting for the control genes PCBD2 (5q31.1) and HMBS (11q23.3): APC (5q22.2), BLK (8p23-p22), TP53 (17p13.1) and DCC (18q21) for losses and EGFR (7p12), C-MYC (8q24.12), ERBB2 (17q12) and STK6 (20q13.31) for gains. Detailed information about the PCR protocol and primer sequences are provided in the Supporting Information (Supporting Information Table 1) . As previously reported, the copy number ratio of each gene was What's new? Small chromosomal changes can have a big impact on cancer survival. In this article, researchers analyzed how colon cancer prognosis was affected by a gain or loss of repeats in microsatellite sequences affected. They collected data on copy number variation at 8 loci from 400 patients with Stage II-III tumors. Two loci stood out: a loss at DCC/18q and a gain at ERBB2/17q both associated with higher risk of relapse, either individually or in combination. Identifying these variants could help with weighing treatment options for localized colon cancer.
Tumor Markers and Signatures
determined by dividing the normalized peak height obtained from the tumor tissue by that observed in the nonmalignant tissue. A peak height ratio > 1.2 is indicative of an increase in the gene copy number in the tumor, whereas a ratio < 0.8 indicates a decrease in the gene copy number. 18 For each patient, the analysis was performed under blind conditions and by at least two independent observers in two independent experiments.
Analysis of the MSS phenotype and KRAS and BRAF mutational status
The MSS phenotype and KRAS (codons 12 and 13) and BRAF (codon 600) mutational status were determined from the DNA extracted from the formalin-fixed, paraffin-embedded tumor tissue. The DNA extraction protocol and the method used to evaluate the MSS phenotype and KRAS/BRAF mutational status (codon 600) were not centralized. The results from each center were integrated in the analysis.
Statistical analysis
The primary end-point was the analysis of the 4-year DFS according to the presence of molecular alterations. The DFS was defined as the time from surgery to the first confirmed local and/or distant relapse. The overall survival was not studied. Patients who died from a non-colon cancer during follow-up were censored at the date of the last follow-up and were not considered to have a proven relapse. Considering an expected prevalence of a molecular alteration of at least 80% and an expected risk of recurrence of approximately 27% at 4 years in Stage II/III colorectal cancer, a sample size of at least 385 Stage II/III patients was calculated under the assumption of a risk of recurrence at 45% in the presence of at least one alteration, with a power of 80%, an alpha value of 5%, and a safety margin of 10%. A descriptive analysis of the baseline clinical and demographic characteristics and molecular alterations was performed, and the variables were tested for the 4-year DFS using a univariate analysis. Only patients in whom all eight target genes were analyzed were considered in the analysis. The survival curves were calculated using the Kaplan-Meier method and compared with the log-rank test. From this result, the factors with a p values <0.20 were selected for a multivariate analysis with Cox's proportional hazard regression (HR) model calculation that was adjusted for age, gender, tumor location, stage, differentiation and KRAS/BRAF status. The proportional hazard assumption was assessed (i) using the graphical approach based on plotting log(-log (S(t))) as a function of log(t), with S(t) denoting DFS at time t, and (ii) by performing an interaction test between each independent variable included in the various considered Cox models and time. No departures from the proportional hazard assumptions were observed. Finally, the alterations identified in the univariate analysis were combined and tested to determine a CNV combination that was associated with DFS. According to the number of alterations, the dose-effect of this profile was analyzed using a multivariate trend test adjusted for the same variables as mentioned above. An interaction test was performed between the stage and each molecular alteration, the presence of at least one molecular alteration, and the CNV combination. The analyses were performed using SAS 9.3 software.
Results
Patient characteristics
A total of 401 patients with MSS colon cancer were included, and their characteristics are listed in Table 1 . There was no significant interaction between the centers and molecular results. The mean age was 70.0 6 11 years, and 236 patients had Stage II disease and 165 patients had Stage III disease. The median follow-up period was 58 months (range 1-117) (Fig. 1a) , with 6 patients lost to follow-up. The overall recurrence rates at 4-years were 20.9%. The 4-year recurrence rate corresponded to 33 Stage II and 51 Stage III patients, respectively (p < 0.0001, Table 1 ). Tumors located on the left side were associated with a poorer 4-year DFS compared with those on the right side (72.5 vs. 85.5%, respectively, p 5 0.012). The site of relapse was local, metastatic or both for 11 (13%), 66 (80%) and 6 (7%) patients, respectively (missing data 5 1). Among the 384 informative patients used for the mutation analysis, 134 (35%) had a mutation in the KRAS gene and 16 (4%) had a mutation in the BRAF gene. There was no significant interaction between the KRAS and/or BRAF mutational status and DFS (Table 1) . The results based on the 5-year follow-up are similar to those at the 4-year follow-up (data not shown).
CNV characteristics
The CNVs from the eight targets were completely analyzed in 377 (94%) patients. At least one CNV was detected in 314 (83%) patients, with a mean of 2.26 61.57 CNVs/sample (Table 2) . A total of 855 (range 0-7) CNVs were detected, corresponding to 347 losses and 508 gains. Among the patients with an informative CNV analysis, 95 (25.1%) had at least four combined alterations. The frequency of each CNV and RAS/BRAF mutational status according to the number of alterations is indicated in Supporting Information Figures 1  and 2 . There was no significant interaction between CNV detection and the disease stage. As shown in Table 2 , losses at APC/5q, BLK/8p, TP53/17p and DCC/18q were detected in 10, 23, 27 and 33% of patients, respectively, and gains at EGFR/7p, MYC/8q, ERBB2/17q and STK6/20q were detected in 32, 36, 19 and 49% of patients, respectively.
CNVs and patient outcome
In the univariate analysis, the 4-year DFS was significantly decreased in patients with a loss at DCC/18q (66.9 vs. 80.3%, p 5 0.012) (Fig. 1b) and in patients with a gain at ERBB2/17q (64.7 vs. 78.5%, p 5 0.0.041) (Fig. 1c) . There was a trend toward a worse DFS in patients with a loss at BLK/8p (70.7 vs. 77.5%, p 5 0.184) and in those with at least one CNV in the eight tested genes (74.4 vs. 83.5%, p 5 0.16) ( Table 2 ). The other CNVs were not associated with DFS. In the multivariate analysis adjusted for age, sex, tumor location, stage,
Tumor Markers and Signatures
Sefrioui et al.
differentiation and KRAS/BRAF status, Stage III (HR 2.7, 95% CI: 1.6-4.4, p 5 0.0001), a loss at DCC/18q (HR 2.0, 95% CI: 1.2-3.5, p 5 0.014) and a gain at ERBB2/17q (HR 1.9, 95% CI: 1.1-3.3, p 5 0.018) were identified as independent factors that were associated with DFS (Table 3) .
Regarding the impact of the CNV combination based on a loss at DCC/18q and a gain at ERBB2/17q, the 4-year DFS decreased from 84.3 to 66.6% and 63.2% in patients with 0, 1 or 2 of these alterations, respectively (p 5 0.0017) (Fig. 1d) . In the multivariate analysis, the DCC/18q and ERBB2/17q combination remained significant, with an adjusted HR increasing from 1 to 2.4 (95% CI: 1.5-4.1) and 3.1 (95% CI: 1.2-8.4) in the presence of 0, 1 or 2 alterations, respectively (p 50.0003) ( Table 4 ).
The analysis of the impact of the CNVs was performed in subgroups that were divided according to whether they had received adjuvant chemotherapy after surgery. There was no significant difference in the prevalence of DCC and ERBB2 CNVs in patients with or without adjuvant chemotherapy (34 vs. 32%, respectively, for DCC and 17 vs. 20%, respectively for ERBB2, Supporting Information Table 2 ). The results of the multivariate analysis (adjusted HR 3.1 and 3.4, respectively) showed that losses at DCC/18q and gains at ERBB2/17q were only informative in the patients who received chemotherapy (Supporting Information Tables 3 and 4 ). The DCC/18q and ERBB2/17q combination was also still associated with the risk of relapse in the subgroup who received adjuvant chemotherapy, with an adjusted HR increasing from 4.7 to 8.8 in patients with 1 or 2 alterations, respectively (Supporting Information  Tables 5 and 6 ).
Discussion
CIN is a backbone event during the carcinogenesis of colon cancer, and the MSS phenotype is observed in approximately 80% of patients, as shown in our work. 6, 11 Although recurrent CNVs have been reported in localized or metastatic tumors, their prognostic value has not yet been clearly validated. 13, [21] [22] [23] [24] In this context, we conducted a prospective study to evaluate the prognostic impact of CIN in MSS Stage II/III colon cancer using the detection of a combination of selected genes and including the mutational status of KRAS and BRAF. Our results showed that a loss at DCC/18q and a gain at ERBB2/17q were independent prognostic factors of DFS, and the combination was also significantly associated with an increased risk of relapse. Moreover, a subgroup analysis according to adjuvant chemotherapy status after surgery showed that DCC/18q and ERBB2/17q were only potentially informative (adjusted HR 3.1 and 3.4, respectively, Supporting Information Data) in patients who received the postoperative treatment. Moreover, we observed that the DCC/18q and ERBB2/17q combination was still associated with the risk of relapse in these patients, with an adjusted HR increasing from 4.7 to 8.8 in patients with 1 or 2 alterations, respectively. These results are interesting from the perspective of personalized adjuvant chemotherapy according to the patient's DCC/18q and ERBB2/17q results. Indeed, to the best of our knowledge, the impact of these CNVs according to Figure 1 . Title. 4-year disease-free survival in all patients and according to CNV at DCC/18d and ERBB2/17q. Legend. The 4-years disease-free survival (DFS) was 79.1% in all patients (a). The 4-year DFS was significantly decreased in patients with a loss at DCC/18q as compared to patients without CNV at this loci (respectively, 66.9 vs. 80.3%, aHR 2.0, 95% CI: 1.2-3.5, p 5 0.014) (b). The 4-year DFS was significantly decreased in patients with a gain at ERBB2/17q (64.7 vs. 78.5%, aHR 1.9, 95% CI: 1.1-3.3, p 5 0.018) as compared to those without CNV at this loci (c). Concerning CNV combination based on loss at DCC/18q and a gain at ERBB2/17q, the 4-year DFS decreased from 84.3 to 66.6% (aHR 2.4, 95% CI: 1.5-4.1) and 63.2% (aHR 3.1, 95% CI: 1.2-8.4) in patients with 0, 1 or 2 of these alterations, respectively (p 5 0.0003) (d).
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adjuvant chemotherapy has not been clearly evaluated. In Watanabe et al. where only losses at 5p, 5q, 17p and 18q were analyzed, a LOH at these loci was associated with poorer DFS in both Stages II and III, but the effect was not specifically analyzed according to adjuvant treatment. 15 On the other hand, in a study that assessed the effect of DCC status by immunohistochemistry on metastases from 42 patients who underwent surgical resection followed by 5FU chemotherapy 6 methotrexate or leucovorin, the presence of DCC negative tumors was associated poorer prognosis than DCC positive tumors. 25 These results could suggest a potential additional effect of CNV and chemotherapy in a postoperative setting. Furthermore, considering that stage is a well-known prognostic factor, the worse outcome of patients receiving adjuvant chemotherapy may be due to the presence of altered DCC and ERBB2 and Stage III in this subgroup as compared to patients without chemotherapy who were mainly at Stage II. Of course, given that the analysis was performed on subgroups, the results need to be considered with caution, and further studies are required to confirm these findings. Finally, we observed that a left tumor was associated with a decreased DFS in the univariate analysis and was within the limits of significance in the multivariate analysis. This discordant result with literature data 26 highlights that the role of tumor site requires further investigations integrating molecular markers, particularly in MSS localized colon cancer. To our knowledge, the prognostic impact of the combination of CNVs at DCC/18q and ERBB2/17q has never been reported in Stage II/III colon cancer. An early loss at 18q is reported to occur in primary tumors, and its prognostic impact has currently been the source of controversy. [27] [28] [29] [30] [31] There are several candidate tumor suppressor genes in the 18q region, such as DCC, SMAD2 and SMAD4. DCC is a transmembrane receptor with structural similarities to members of the neural cell adhesion molecule family. 32 Its expression is reduced in >50% of colorectal tumors, as well as various cancers. The role of DCC as a tumor suppressor in colon carcinogenesis has been a matter of debate for several years, primarily due to a lack of support from animal models. However, it has been recently reported that DCC is a ligand-dependent receptor that requires an available ligand to mediate cellular survival. 33, 34 This function may confer the role of tumor suppressor on DCC, such that it eliminates abnormally growing cells in situations where there are low levels of ligands. As shown in our study, a loss at DCC/18q is associated with the risk of relapse and may reflect an alteration in this regulatory function of DCC, leading to tumor progression. In the study by Watanabe et al. a loss at 18q was associated with a decrease in DFS from 75.2 to 62%, which was similar to our results. 15 A meta-analysis of 27 studies reported that cancers with a loss at 18q were more likely to have a worse prognosis, with an HR of 1.69 for the overall survival (95% CI: 1.13-2.54) of patients who were treated for localized tumors. 27 However, the presence of several publication biases limited the conclusion, and the need for a prospective validation with consistent methodology was clearly highlighted. Indeed, there was evidence of heterogeneity in the criteria used for patient selection, with approximately one-third of studies including Stage IV patients. Finally, many of these studies did not consider the effect of some important confounding factors, such as the MSS/MSI phenotype or KRAS/BRAF mutational status. Two recent retrospective studies showed that MSI and a high level of CIN, based on an analysis of the CNV ratio and representing a loss of heterozygosity at 2p, 5q, 18q, 17p, 5q, 17p or 18q, were associated with patient outcome. 15, 16 A similar trend was observed in our study, where a larger number of CNVs, which corresponded to the presence of at least 3 of the 8 targeted alterations or a ratio 37.5%, was associated with a decrease in the 4 year DFS (adjusted HR 1.7, p 5 0.034, data not shown). Taken together, these results suggested that CIN may play a prognostic role in colon cancer and that specific regions such as 18q and 17q are particularly involved in the risk of relapse. Indeed, we found that the combination of DCC/ 18q and ERBB2/17q that was identified by the univariate and multivariate analyses was relevant in predicting the 4-year DFS, with an adjusted HR increasing from 1 to 2.4 (95% CI: 1.5-4.1) and 3.1 (95% CI: 1.2-48.4) in the presence of 0, 1 or 2 alterations, respectively. An additional analysis of a cohort harboring the same main characteristics (MSS, colon cancer, KRAS and BRAF testing) may be of interest in determining the respective prognostic value of the CNV ratio and DCC/18q and ERBB2/ 17q combination. ERBB2 is an oncogene located on chromosome 17 (17q21-q22), and a gain at 17q has been reported to be a CNV that is preferentially associated with the progression from a primary colorectal tumor to metastasis. 13, 22 HER2 belongs to the epidermal growth factor receptor (EGFR/ErbB) family, which also includes EGFR, HER3 (ErbB-3) and HER4 (ErbB-4). The EGFR family is involved in cell proliferation and survival by activating the RAS/RAF/ERK and PIK/PTEN/AKT pathways. 35 Overexpression of ERBB2 is known as an therapeutic target in breast and gastric cancers, and a variety of anti-ERBB2 agents has been successfully exploited in the clinic, leading to remarkable improvements in the patients' outcomes. 36, 37 The copy number of the ERBB2 gene was found to be associated with the 
patient outcome in a series of 170 patients with wild-type KRAS and metastatic colorectal cancer who were treated with anti-EGFR therapy. 38, 39 Similar to our study, the rate of a gain in the ERBB2 copy number was higher than expected and was observed in 20% of the patients. Interestingly, the request of the TCGA database for alterations in ERBB2 and DCC genes in colorectal cancer cohorts using the cBioPortal for Cancer Genomics from Memorial Sloan Kettering Cancer supported our findings. 40, 41 Indeed, among the two datasets reporting CNVs at these loci (N 5 220 and N 5 212), the gain and amplification at ERBB2 were 18.9 and 26.8%, whereas the rate of loss at DCC was 41.8 and 46.8% in the two cohorts (Supporting Information  Fig. 3) . Interestingly, the analysis of the outcome in 189 patients from the TCGA cohort 1 showed similar findings as in our study with a trend for an inferior DFS in patients with loss of DCC and a gain at ERBB2 as compared to patients without these CNVs (median 40.1 months vs. NA, respectively, p 5 0.242, Supporting Information Fig. 4 ). Taken together, these findings were similar to ours, including for ERBB2 for which the entire detection of gain copy number, including gain and amplification, is considered. Alternatively, in the metaanalysis of Diep et al. the gain of ERBB2 detected using CGH methods was different according to the tumor sites and was reported to be 7% in the primary site and 20% in liver metastases. 13 From a clinical point of view, the combination of the anti-ERBB2 monoclonal antibody trastuzumab and the dual EGFR/HER2 small-molecule inhibitor lapatinib has been shown to be potentially effective in treating ERBB2-amplified metastatic CRC. 42 Indeed, the HERACLES trial, a phase II trial testing the combination of these two target therapies, has been conducted in ERBB2-positive metastatic colorectal cancer patients who were refractory to standard treatments, including cetuximab or panitumumab. Based on a prevalence of 5% of ERBB2 amplification in the screened patients, the study reported positive results, with a response rate of 35% and median time to progression of 5.5 months. 43 While a determination of the ERBB2 status in colon cancer tissue is not yet routinely performed, all of these results demonstrate that CNVs in ERBB2 may play a key role in a subgroup of colon cancer patients and that its detection may be relevant to identifying patients with a significant risk of relapse and those who may respond to these inhibitors. Of course, a validation in an independent cohort is needed to confirm these results.
The frequencies of CNVs in the other genes analyzed in our study were consistent with the previously reported frequencies. 13, 18, 21, 44 In a meta-analysis of 31 studies based on CGH methods and including 859 colorectal cancer patients, of whom 720 had primary tumors and 139 had liver metastases, the CNVs observed in primary tumors were relatively similar to our results with 50, 28, 23 and 13% of patients displaying losses at 18q, 17p, 8p and 5q and 28, 33 and 50% of patients displaying gains at 7p, 8q and 20q, respectively. 13 These results demonstrated that the method used in our work, which has been developed to detect CNVs in selected targets in both inherited and somatic malignancies, showed a good overall concordance with other molecular quantitative methods, such as real-time quantitative PCR or CGH. 18 Considering that DCC and ERBB2 were CNVs of clinical interest in our study, a set of 58 samples with sufficient DNA quality, corresponding to 30 controls and 28 positives cases in QMPSF, was used to show the concordance of QMPSF with an ultrasensitive droplet-based dPCR (ddPCR) method (Qx200V R ddPCR system, Bio-Rad, Hercules, CA, USA) (see Supporting Information Table 7 and Supporting Information Figs. 5 and 6) . 45, 46 Overall, the concordance rate was 75% between the two methods, supporting as previsouly reported, that QMPSF allows CNVs detection in equivalent proportions than other methods. 18, 47, 48 Some limitations were present in our study. Indeed, the storage of samples from the sites of relapse was not planned in the protocol, and these tissues were not available to analyze the relationship between the CNVs in the primary tumors and metastases. Moreover, while CNVs at the DCC/18q and ERBB2/17q loci were identified in a multivariate analysis, it will also be relevant to test their value in an independent cohort of patients with Stage II/III disease, while integrating other markers, such as recent prognostic molecular classifications. [8] [9] [10] In conclusion, the results of the present study showed that a loss at DCC/18q and a gain at ERBB2/17q were associated with a worse DFS in Stage II/II MSS colon cancer patients. CNVs at these loci were identified as independent prognostic factors of DFS, and their combination was also significantly associated with an increased risk of relapse.
